June 2018 – Cancer Immunotherapy
New developments in immunotherapy drugs continue to create buzz in the cancer community and beyond. This special issue discusses key developments in immunotherapy, highlighting new advances and providing resources for patients, their family members, and their oncology navigators.
By Jane Morgan
Several immune checkpoint inhibitors are now approved for patients with non-small-cell lung cancer, giving hope to patients living with this disease.
“CAR T-cell therapy provides an exciting and additional option for patients who have failed more traditional regimens,” says Dr. Gwen Nichols, Chief Medical Officer for Leukemia & Lymphoma Society.
By Wayne Kuznar
The National Comprehensive Cancer Care Network and the American Society of Clinical Oncology recently issued the first set of recommendations for the management of immunotherapy side-effects.
SurvivorshipWork & Cancer
Cancer treatment costs, and the desire for normalcy and self-worth, are some of the reasons why patients with cancer wish to remain in the workforce.
Results 1 - 7 of 7